van Winkel Suzanne L, Samperna Riccardo, Loehrer Elizabeth A, Kroes Jaap, Rodriguez-Ruiz Alejandro, Mann Ritse M
From the Department of Medical Imaging, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, the Netherlands (S.L.v.W., R.S., E.A.L., R.M.M.); Department of Ethics, Law and Humanities, Amsterdam University Medical Centers, Amsterdam, the Netherlands (S.L.v.W.); Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, the Netherlands (E.A.L.); ScreenPoint Medical, Nijmegen, the Netherlands (J.K., A.R.R.); and Department of Radiology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands (R.M.M.).
Radiology. 2025 Feb;314(2):e233067. doi: 10.1148/radiol.233067.
Background Combined mammography and MRI screening is not universally accessible for women with intermediate breast cancer risk due to limited MRI resources. Selecting women for MRI by assessing their mammogram may enable more resource-effective screening. Purpose To explore the feasibility of using a commercial artificial intelligence (AI) system at mammography to stratify women with intermediate risk for supplemental MRI or no MRI. Materials and Methods This retrospective study included consecutive women with intermediate risk screened with mammography and MRI between January 2003 and January 2020 at a Dutch university medical center. An AI system was used to independently evaluate all mammograms, providing a case-based score that ranked the likelihood of a malignancy on a scale of 1-10. Different AI thresholds for supplemental MRI screening were tested, balancing cancer detection against the number of women needing to undergo MRI. Univariate analyses were used to explore associations between personal factors (age, breast density, and duration of screening participation) and AI results. Results In 760 women (mean age, 48.9 years ± 10.5 [SD]), 2819 combined screening examinations were performed, and 37 breast cancers were detected. Use of AI at mammography achieved an area under the receiver operating characteristic curve of 0.72 (95% CI: 0.63, 0.81) for the entire intermediate-risk population and 0.81 (95% CI: 0.69, 0.93) for women with prior breast cancer. Using a threshold score of 5, 31 of 37 (84%) breast cancers were detected, including 13 of 19 (68%) mammographically occult cancers, at a supplemental breast MRI rate of 50% (1409 of 2819 examinations). No significant association between breast density or age and the probability of a false-negative AI result was found. Conclusion Using AI at mammography to select women for supplemental MRI effectively identified women with higher breast cancer risk in an intermediate-risk population, including women with mammographically occult cancers. AI selection of women with intermediate risk for supplemental MRI screening has the potential to reduce screening burden and costs, while maintaining a high cancer detection rate. © RSNA, 2025.
背景 由于磁共振成像(MRI)资源有限,对于具有中度乳腺癌风险的女性而言,乳腺钼靶联合MRI筛查并非普遍可行。通过评估乳腺钼靶检查结果来选择进行MRI检查的女性,可能会使筛查资源更有效利用。目的 探讨在乳腺钼靶检查中使用商业人工智能(AI)系统对中度风险女性进行分层,以确定其是否需要补充MRI检查或无需进行MRI检查的可行性。材料与方法 这项回顾性研究纳入了2003年1月至2020年1月期间在荷兰一家大学医学中心接受乳腺钼靶和MRI筛查的连续的中度风险女性。使用AI系统独立评估所有乳腺钼靶检查结果,提供基于病例的评分,该评分在1-10的范围内对恶性肿瘤的可能性进行排名。测试了用于补充MRI筛查的不同AI阈值,在癌症检测与需要接受MRI检查的女性数量之间进行权衡。单因素分析用于探讨个人因素(年龄、乳腺密度和筛查参与时间)与AI结果之间的关联。结果 在760名女性(平均年龄48.9岁±10.5[标准差])中,进行了2819次联合筛查检查,检测出37例乳腺癌。在乳腺钼靶检查中使用AI,对于整个中度风险人群,受试者操作特征曲线下面积为0.72(95%CI:0.63,0.81);对于既往有乳腺癌的女性,该面积为0.81(95%CI:0.69,0.93)。使用阈值分数5时,在37例乳腺癌中检测出31例(84%),包括19例乳腺钼靶隐匿性癌中的13例(68%),补充乳腺MRI检查率为50%(2819次检查中的1409次)。未发现乳腺密度或年龄与AI假阴性结果概率之间存在显著关联。结论 在乳腺钼靶检查中使用AI选择女性进行补充MRI检查,可有效识别中度风险人群中乳腺癌风险较高的女性,包括乳腺钼靶隐匿性癌患者。AI选择中度风险女性进行补充MRI筛查有可能减轻筛查负担和成本,同时保持较高的癌症检测率。©RSNA,2025年